Menu
Search
|

Menu

Close
X

Agenus Inc AGEN.OQ (NASDAQ Stock Exchange Capital Market)

2.06 USD
+0.07 (+3.52%)
As of Nov 14
chart
Previous Close 1.99
Open 2.01
Volume 235,799
3m Avg Volume 218,768
Today’s High 2.11
Today’s Low 1.99
52 Week High 6.19
52 Week Low 1.55
Shares Outstanding (mil) 87.00
Market Capitalization (mil) 409.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
30
FY17
43
FY16
23
FY15
25
EPS (USD)
FY18
-1.052
FY17
-1.220
FY16
-1.461
FY15
-1.152
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
9.95
5.95
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
--
17.74
LT Debt to Equity (MRQ)
vs sector
--
13.15
Return on Investment (TTM)
vs sector
-75.39
14.22
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Garo Armen
Chairman of the Board, Chief Executive Officer, Founder, Since 1994
Salary: $592,788.00
Bonus: $486,000.00
Alexander Duncan
Chief Technology Officer and Head - Research, Since 2017
Salary: $314,705.00
Bonus: $175,000.00
Christine Klaskin
Principal Accounting Officer, Since 2018
Salary: $250,000.00
Bonus: $105,000.00
Evan Kearns
Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Karen Valentine
General Counsel, Chief Legal Officer, Since 2015
Salary: $347,115.00
Bonus: $210,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3 Forbes Rd
LEXINGTON   MA   02421-7305

Phone: +1781.6744400

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

SPONSORED STORIES